A phase 3 randomized and double-blind controlled trial comparing the efficacy and safety of subcutaneous belimumab or placebo in addition to rituximab in adult patients with persistent or chronic immune thrombocytopenia (ITP) (RITUX-PLUS 2)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belimumab (Primary) ; Rituximab (Primary)
Indications Idiopathic thrombocytopenic purpura
Focus Therapeutic Use
Acronyms RITUX-PLUS 2

Most Recent Events

08 Sep 2023 Planned End Date changed from 1 Jun 2027 to 14 Nov 2027.
08 Sep 2023 Planned primary completion date changed from 1 Jun 2026 to 14 Nov 2026.
11 Feb 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight